Ernexa Therapeutics Inc. Noncash Merger Related Costs
Ernexa Therapeutics Inc. (ERNA) reported Noncash Merger Related Costs of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashMergerRelatedCosts · last filed 2023-03-20
- Ernexa Therapeutics Inc. noncash merger related costs for the quarter ending 2022-12-31 was $0.00.
- Ernexa Therapeutics Inc. noncash merger related costs for the quarter ending 2022-09-30 was $0.00.
- Ernexa Therapeutics Inc. noncash merger related costs for the quarter ending 2022-06-30 was $0.00.
- Ernexa Therapeutics Inc. noncash merger related costs for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- Ernexa Therapeutics Inc. noncash merger related costs for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Ernexa Therapeutics Inc. noncash merger related costs for fiscal 2021 was $5.76M.
- Ernexa Therapeutics Inc. noncash merger related costs for fiscal 2020 was $0.00.
| Period end | Noncash Merger Related Costs 3 month | Noncash Merger Related Costs 3 month as first filed | Noncash Merger Related Costs 6 month | Noncash Merger Related Costs 6 month as first filed | Noncash Merger Related Costs 9 month | Noncash Merger Related Costs 9 month as first filed | Noncash Merger Related Costs 12 month |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $0.00 10-K · filed 2023-03-20 | |||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 4 quarters · filed 2023-03-20 | |||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 | $0.00 10-Q · filed 2022-08-11 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $0.00 derived: sum of 4 quarters · filed 2023-03-20 | |||
| 2022-03-31 | $0.00 10-Q · filed 2022-07-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $0.00 derived: sum of 4 quarters · filed 2023-03-20 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $5.76M 10-K · filed 2023-03-20 | |||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $5.76M 10-Q · filed 2022-11-14 | $5.77M 10-Q · filed 2021-11-12 | $5.76M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | $5.76M 10-Q · filed 2022-08-11 | $5.77M 10-Q · filed 2021-08-13 | $5.76M derived: sum of 3 quarters · filed 2022-08-11 | $5.76M derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $5.76M 10-Q · filed 2022-07-01 | $5.77M 10-Q · filed 2021-05-17 | $5.76M derived: sum of 2 quarters · filed 2022-07-01 | $5.76M derived: sum of 3 quarters · filed 2022-07-01 | $5.76M derived: sum of 4 quarters · filed 2022-07-01 | ||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-01 | $0.00 derived: sum of 2 quarters · filed 2022-07-01 | $0.00 derived: sum of 3 quarters · filed 2022-07-01 | $0.00 10-K/A · filed 2022-07-01 | |||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | ||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-13 | $0.00 10-Q · filed 2021-08-13 | |||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |